JP Morgan 2024 – Trevor Martin

Last month’s JP Morgan conference came not too long after the FDA’s historic clearance of the first CRISPR-derived gene therapy. So, it’s no surprise that gene therapy, and the future of CRISPR-based therapies in particular, was a hot topic.

In San Francisco last month, during the show editor-in-chief Jonah Comstock caught up with Trevor Martin, co-founder and CEO of Mammoth Biosciences, a company that is looking into new kinds of in vivo CRISPR systems beyond CRISPR-Cas9.

Martin discusses how smaller, easier to deliver payloads can be used to treat conditions in new areas of the body and allow for more complex gene editing methods.

They also discuss the role AI has played in discovering the microorganisms that might harbour these new systems, as well as the logistical and infrastructure challenges that still plague the cell and gene therapy space.

Check out the video for a taste of what comes next in one of the most hotly-discussed areas of biotech innovation.